Current approaches to fine mapping of antigen–antibody interactions

A number of different methods are commonly used to map the fine details of the interaction between an antigen and an antibody. Undoubtedly the method that is now most commonly used to give details at the level of individual amino acids and atoms is X‐ray crystallography. The feasibility of undertaking crystallographic studies has increased over recent years through the introduction of automation, miniaturization and high throughput processes. However, this still requires a high level of sophistication and expense and cannot be used when the antigen is not amenable to crystallization. Nuclear magnetic resonance spectroscopy offers a similar level of detail to crystallography but the technical hurdles are even higher such that it is rarely used in this context. Mutagenesis of either antigen or antibody offers the potential to give information at the amino acid level but suffers from the uncertainty of not knowing whether an effect is direct or indirect due to an effect on the folding of a protein. Other methods such as hydrogen deuterium exchange coupled to mass spectrometry and the use of short peptides coupled with ELISA‐based approaches tend to give mapping information over a peptide region rather than at the level of individual amino acids. It is quite common to use more than one method because of the limitations and even with a crystal structure it can be useful to use mutagenesis to tease apart the contribution of individual amino acids to binding affinity.

[1]  S. Meeks,et al.  Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen–deuterium exchange mass spectrometry , 2013, Journal of thrombosis and haemostasis : JTH.

[2]  J. Voorberg,et al.  Factor VIII C1 Domain Spikes 2092–2093 and 2158–2159 Comprise Regions That Modulate Cofactor Function and Cellular Uptake , 2013, The Journal of Biological Chemistry.

[3]  Ya-jun Guo,et al.  Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor alpha-associated diseases from a molecular view , 2013 .

[4]  Ya-jun Guo,et al.  Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View* , 2013, The Journal of Biological Chemistry.

[5]  J. Benschop,et al.  Characterization of the complex formed between a potent neutralizing ovine-derived polyclonal anti-TNFα Fab fragment and human TNFα , 2013, Bioscience reports.

[6]  C. Lindsley The top prescription drugs of 2012 globally: biologics dominate, but small molecule CNS drugs hold on to top spots. , 2013, ACS chemical neuroscience.

[7]  Peng Zhou,et al.  Epitope Mapping of Metuximab on CD147 Using Phage Display and Molecular Docking , 2013, Comput. Math. Methods Medicine.

[8]  L. Huerta,et al.  HIV-1 V3 loop crown epitope-focused mimotope selection by patient serum from random phage display libraries: implications for the epitope structural features. , 2013, Molecular immunology.

[9]  Xi Song,et al.  Crystal structures of interleukin 17A and its complex with IL-17 receptor A , 2013, Nature Communications.

[10]  Nicola Clementi,et al.  Characterization of epitopes recognized by monoclonal antibodies: experimental approaches supported by freely accessible bioinformatic tools. , 2013, Drug discovery today.

[11]  M. Ultsch,et al.  Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. , 2013, Journal of molecular biology.

[12]  Z. Rao,et al.  Structural Basis for Treating Tumor Necrosis Factor α (TNFα)-associated Diseases with the Therapeutic Antibody Infliximab* , 2013, The Journal of Biological Chemistry.

[13]  Mathias Hafner,et al.  One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β. , 2013, Journal of molecular biology.

[14]  R. Stevens,et al.  Structure-function of the G protein-coupled receptor superfamily. , 2013, Annual review of pharmacology and toxicology.

[15]  C. Bokemeyer,et al.  Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. , 2012, Neoplasia.

[16]  Bjoern Peters,et al.  The immune epitope database: a historical retrospective of the first decade , 2012, Immunology.

[17]  P. Wilson,et al.  Tools to therapeutically harness the human antibody response , 2012, Nature Reviews Immunology.

[18]  D. Scott,et al.  Epitope mapping by random peptide phage display reveals essential residues for vaccinia extracellular enveloped virion spread , 2012, Virology Journal.

[19]  Yanay Ofran,et al.  Paratome: an online tool for systematic identification of antigen-binding regions in antibodies based on sequence or structure , 2012, Nucleic Acids Res..

[20]  S. Tuske,et al.  Mapping of discontinuous conformational epitopes by amide hydrogen/deuterium exchange mass spectrometry and computational docking , 2012, Journal of molecular recognition : JMR.

[21]  Yanay Ofran,et al.  Structural Consensus among Antibodies Defines the Antigen Binding Site , 2012, PLoS Comput. Biol..

[22]  R. Minter,et al.  A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency , 2012, Cell Death and Differentiation.

[23]  Herren Wu,et al.  Structural and functional characterization of an agonistic anti-human EphA2 monoclonal antibody. , 2011, Journal of molecular biology.

[24]  John Corbin,et al.  XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases , 2011, mAbs.

[25]  Y. Yoshioka,et al.  Solution of the Structure of the TNF-TNFR2 Complex , 2010, Science Signaling.

[26]  Jinquan Luo,et al.  Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. , 2010, Journal of molecular biology.

[27]  P. Larsen,et al.  Kinetic Approach to Pathway Attenuation Using XOMA 052, a Regulatory Therapeutic Antibody That Modulates Interleukin-1β Activity , 2010, The Journal of Biological Chemistry.

[28]  Michael Mahler,et al.  Epitope specificity and significance in systemic autoimmune diseases , 2010, Annals of the New York Academy of Sciences.

[29]  Jianping Ding,et al.  Structural Basis for the Blockage of IL-2 Signaling by Therapeutic Antibody Basiliximab , 2009, The Journal of Immunology.

[30]  S. Tuske,et al.  Structure of IL-17A in complex with a potent, fully human neutralizing antibody. , 2009, Journal of molecular biology.

[31]  Lihua Huang,et al.  Determination of the mechanism of action of anti-FasL antibody by epitope mapping and homology modeling. , 2009, Biochemistry.

[32]  G. Gilliland,et al.  Epitope mapping of anti-interleukin-13 neutralizing antibody CNTO607. , 2009, Journal of molecular biology.

[33]  J. Rucker,et al.  Atomic-level mapping of antibody epitopes on a GPCR. , 2009, Journal of the American Chemical Society.

[34]  Di Wu,et al.  SEPPA: a computational server for spatial epitope prediction of protein antigens , 2009, Nucleic Acids Res..

[35]  S. Tuske,et al.  Epitope mapping by amide hydrogen/deuterium exchange coupled with immobilization of antibody, on-line proteolysis, liquid chromatography and mass spectrometry. , 2009, Rapid communications in mass spectrometry : RCM.

[36]  Damon L. Meyer,et al.  A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. , 2008, Cancer research.

[37]  P. Orth,et al.  Crystal structures of the pro-inflammatory cytokine interleukin-23 and its complex with a high-affinity neutralizing antibody. , 2008, Journal of Molecular Biology.

[38]  A. Poustka,et al.  Combinatorial synthesis of peptide arrays with a laser printer. , 2008, Angewandte Chemie.

[39]  Siyi Hu,et al.  Epitope mapping and structural analysis of an anti‐ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism , 2008, Proteins.

[40]  Yong-Sung Kim,et al.  Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. , 2007, Journal of molecular biology.

[41]  M. Burghammer,et al.  Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.

[42]  D. Nikolov,et al.  Cell-cell signaling via Eph receptors and ephrins. , 2007, Current opinion in cell biology.

[43]  R. Meloen,et al.  Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS™ technology , 2007, Journal of molecular recognition : JMR.

[44]  Jesse D. Martinez,et al.  Loss of p53 and overexpression of EphA2 predict poor prognosis for ovarian cancer patients , 2007, Cancer biology & therapy.

[45]  Leonard A. Smith,et al.  Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. , 2007, Journal of molecular biology.

[46]  R. Ladner Mapping the Epitopes of Antibodies , 2007, Biotechnology & genetic engineering reviews.

[47]  S. Englander Hydrogen exchange and mass spectrometry: A historical perspective , 2006, Journal of the American Society for Mass Spectrometry.

[48]  P. Parren,et al.  The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201 , 2006, The Journal of Immunology.

[49]  H. Kuwano,et al.  Evaluation of tumor malignancy in esophageal squamous cell carcinoma using different characteristic factors. , 2005, Anticancer research.

[50]  J. M. Beals,et al.  IL-1β Epitope Mapping Using Site-Directed Mutagenesis and Hydrogen−Deuterium Exchange Mass Spectrometry Analysis , 2005 .

[51]  A. Plückthun,et al.  Directed in Vitro Evolution and Crystallographic Analysis of a Peptide-binding Single Chain Antibody Fragment (scFv) with Low Picomolar Affinity* , 2004, Journal of Biological Chemistry.

[52]  K. Strauch,et al.  Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody. , 2001, Structure.

[53]  A. D. de Vos,et al.  Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. , 1999, Journal of molecular biology.

[54]  Neil S. Greenspan,et al.  Defining epitopes: It's not as easy as it seems , 1999, Nature Biotechnology.

[55]  A. D. de Vos,et al.  VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. , 1998, Structure.

[56]  G. Ligtvoet,et al.  Structural aspects of antibody-antigen interaction revealed through small random peptide libraries , 1996, Molecular Diversity.

[57]  A. Gronenborn,et al.  Complete resonance assignment for the polypeptide backbone of interleukin 1 beta using three-dimensional heteronuclear NMR spectroscopy. , 1990, Biochemistry.

[58]  A. Lesk,et al.  Canonical structures for the hypervariable regions of immunoglobulins. , 1987, Journal of molecular biology.

[59]  T. T. Wu,et al.  AN ANALYSIS OF THE SEQUENCES OF THE VARIABLE REGIONS OF BENCE JONES PROTEINS AND MYELOMA LIGHT CHAINS AND THEIR IMPLICATIONS FOR ANTIBODY COMPLEMENTARITY , 1970, The Journal of experimental medicine.

[60]  Guodong Chen,et al.  Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications. , 2014, Drug discovery today.

[61]  Søren B. Padkjær,et al.  Structural analysis of B-cell epitopes in antibody:protein complexes. , 2013, Molecular immunology.

[62]  J. Langedijk,et al.  Structure-based design for high-hanging vaccine fruits. , 2012, Advances in immunology.

[63]  A. Böttger,et al.  Epitope mapping using phage display peptide libraries. , 2009, Methods in molecular biology.

[64]  U. Reineke Antibody epitope mapping using de novo generated synthetic peptide libraries. , 2009, Methods in molecular biology.

[65]  Mathieu Rouard,et al.  IMGT unique numbering for immunoglobulin and T cell receptor constant domains and Ig superfamily C-like domains. , 2005, Developmental and comparative immunology.